MA47130A - Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations - Google Patents

Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Info

Publication number
MA47130A
MA47130A MA047130A MA47130A MA47130A MA 47130 A MA47130 A MA 47130A MA 047130 A MA047130 A MA 047130A MA 47130 A MA47130 A MA 47130A MA 47130 A MA47130 A MA 47130A
Authority
MA
Morocco
Prior art keywords
human
specifically binding
antibodies specifically
antibodies
binding
Prior art date
Application number
MA047130A
Other languages
English (en)
Other versions
MA47130B1 (fr
Inventor
Adam William Clarke
Anthony Gerard Doyle
David Jose Simon Laine
Matthew Pollard
Lynn Dorothy Poulton
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MA47130A publication Critical patent/MA47130A/fr
Publication of MA47130B1 publication Critical patent/MA47130B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
MA47130A 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations MA47130B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
EP17883800.9A EP3558369B1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
PCT/US2017/067917 WO2018119246A1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Publications (2)

Publication Number Publication Date
MA47130A true MA47130A (fr) 2019-10-30
MA47130B1 MA47130B1 (fr) 2025-05-30

Family

ID=62627610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47130A MA47130B1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Country Status (30)

Country Link
US (2) US11267883B2 (fr)
EP (2) EP3558369B1 (fr)
JP (2) JP7155126B2 (fr)
KR (2) KR102706743B1 (fr)
CN (1) CN110234349B (fr)
AR (1) AR110414A1 (fr)
AU (2) AU2017382850B2 (fr)
BR (1) BR112019012570A8 (fr)
CA (1) CA3046387A1 (fr)
CL (1) CL2019001729A1 (fr)
DK (1) DK3558369T3 (fr)
EA (1) EA201991514A1 (fr)
ES (1) ES3026508T3 (fr)
FI (1) FI3558369T3 (fr)
HR (1) HRP20250482T1 (fr)
HU (1) HUE071878T2 (fr)
IL (1) IL267113B2 (fr)
LT (1) LT3558369T (fr)
MA (1) MA47130B1 (fr)
MD (1) MD3558369T2 (fr)
MX (2) MX2019007357A (fr)
PE (1) PE20191497A1 (fr)
PH (1) PH12019501453A1 (fr)
PL (1) PL3558369T3 (fr)
PT (1) PT3558369T (fr)
RS (1) RS66900B1 (fr)
SI (1) SI3558369T1 (fr)
UA (1) UA126284C2 (fr)
WO (1) WO2018119246A1 (fr)
ZA (1) ZA201903848B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4610368B1 (fr) 2013-08-05 2026-02-04 Twist Bioscience Corporation Banques de gènes synthétisés de novo
WO2016126882A1 (fr) 2015-02-04 2016-08-11 Twist Bioscience Corporation Procédés et dispositifs pour assemblage de novo d'acide oligonucléique
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
IL258164B (en) 2015-09-18 2022-09-01 Twist Bioscience Corp Methods for modulating protein and cellular activity and method for nucleic acid synthesis
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
PL3558369T3 (pl) 2016-12-21 2025-06-23 Cephalon Llc Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania
EP4556433A3 (fr) 2017-02-22 2025-08-06 Twist Bioscience Corporation Stockage de données à base d'acide nucléique
WO2018231864A1 (fr) 2017-06-12 2018-12-20 Twist Bioscience Corporation Méthodes d'assemblage d'acides nucléiques continus
CN111566209B (zh) 2017-06-12 2024-08-30 特韦斯特生物科学公司 无缝核酸装配方法
EP3681906A4 (fr) 2017-09-11 2021-06-09 Twist Bioscience Corporation Protéines se liant au gpcr et leurs procédés de synthèse
KR102889470B1 (ko) 2017-10-20 2025-11-21 트위스트 바이오사이언스 코포레이션 폴리뉴클레오타이드 합성을 위한 가열된 나노웰
CA3088911A1 (fr) 2018-01-04 2019-07-11 Twist Bioscience Corporation Dispositif de stockage a base d'adn et methode de synthese de polynucleotides utilisant le dispositif
WO2019222706A1 (fr) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucléotides, réactifs, et procédés d'hybridation d'acides nucléiques
WO2020023702A1 (fr) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
CA3124980A1 (fr) 2018-12-26 2020-07-02 Twist Bioscience Corporation Synthese de novo polynucleotidique hautement precise
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
CN113785057A (zh) 2019-02-26 2021-12-10 特韦斯特生物科学公司 用于抗体优化的变异核酸文库
WO2020252264A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021061842A1 (fr) 2019-09-23 2021-04-01 Twist Bioscience Corporation Bibliothèques d'acides nucléiques variants pour des anticorps à domaine unique
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
EP4229093A1 (fr) * 2020-10-16 2023-08-23 Genentech, Inc. Anticorps dirigés contre le substrat de icaspase clivée et méthodes d'utilisation
KR20230147617A (ko) 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
CA3263439A1 (fr) 2022-08-04 2024-02-08 Novartis Pharma Ag Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (fr) 2024-04-26 2025-10-30 Cephalon Llc Doses et formulations d'anticorps anti-il-15 pour le traitement de maladies immunitaires

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
PL217752B1 (pl) * 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CN1780856A (zh) * 2003-02-26 2006-05-31 根马布股份公司 白介素15(il－15)的特异性人抗体
TW200619227A (en) * 2004-08-11 2006-06-16 Hoffmann La Roche Mutant interleukin-15-containing compositions and suppression of an immune response
WO2006090750A1 (fr) * 2005-02-28 2006-08-31 Institute For Antibodies Co., Ltd. Anticorps anti-igsf4 et son utilisation
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
KR102096731B1 (ko) 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
CN102655880A (zh) * 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
WO2011119484A1 (fr) * 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides
CA2805653A1 (fr) * 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anticorps specifiques anti-heterodimere il-23
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
WO2013026832A1 (fr) * 2011-08-23 2013-02-28 Roche Glycart Ag Anticorps anti-mcsp
EP3559049B1 (fr) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
CN110845618A (zh) * 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2963057A1 (fr) * 2014-07-02 2016-01-06 Calypso Biotech SA Anticorps pour IL-15
MY190209A (en) 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
MX2018015363A (es) * 2016-06-15 2019-04-15 Amgen Inc Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
PL3558369T3 (pl) 2016-12-21 2025-06-23 Cephalon Llc Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania

Also Published As

Publication number Publication date
CN110234349A (zh) 2019-09-13
AU2025201185A1 (en) 2025-03-13
ZA201903848B (en) 2023-02-22
HRP20250482T1 (hr) 2025-06-20
EP3558369A1 (fr) 2019-10-30
EP4585261A2 (fr) 2025-07-16
AU2017382850B2 (en) 2024-11-21
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
PH12019501453A1 (en) 2020-06-15
BR112019012570A2 (pt) 2019-11-26
EA201991514A1 (ru) 2019-12-30
KR20190097094A (ko) 2019-08-20
KR102706743B1 (ko) 2024-09-19
BR112019012570A8 (pt) 2023-01-24
PT3558369T (pt) 2025-05-06
AR110414A1 (es) 2019-03-27
LT3558369T (lt) 2025-07-25
US20200270339A1 (en) 2020-08-27
KR20230135691A (ko) 2023-09-25
MA47130B1 (fr) 2025-05-30
MX2023014081A (es) 2023-12-06
US11267883B2 (en) 2022-03-08
WO2018119246A1 (fr) 2018-06-28
US20220127352A1 (en) 2022-04-28
JP2022176324A (ja) 2022-11-25
MD3558369T2 (ro) 2025-08-31
HUE071878T2 (hu) 2025-09-28
PL3558369T3 (pl) 2025-06-23
SI3558369T1 (sl) 2025-06-30
IL267113A (en) 2019-08-29
DK3558369T3 (da) 2025-05-19
MX2019007357A (es) 2019-09-05
CA3046387A1 (fr) 2018-06-28
EP3558369B1 (fr) 2025-03-26
FI3558369T3 (fi) 2025-05-02
IL267113B1 (en) 2024-05-01
UA126284C2 (uk) 2022-09-14
IL267113B2 (en) 2024-09-01
CN110234349B (zh) 2024-03-22
JP7155126B2 (ja) 2022-10-18
PE20191497A1 (es) 2019-10-21
EP4585261A3 (fr) 2025-08-13
US12410247B2 (en) 2025-09-09
JP2020501583A (ja) 2020-01-23
ES3026508T3 (en) 2025-06-11
RS66900B1 (sr) 2025-07-31
EP3558369A4 (fr) 2020-09-09

Similar Documents

Publication Publication Date Title
MA47130A (fr) Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3634995A4 (fr) Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3370769A4 (fr) Anticorps se liant spécifiquement à tim-3 et leurs utilisations
MA44723A (fr) Anticorps agonistes se liant au cd40 humain et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
EP3362479A4 (fr) Agents de type anticorps spécifiques de l'antigène cd19 humain et leurs utilisations
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
EP3681912A4 (fr) Anticorps spécifiques d'axl et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations